BRAIN CANCER

For Brain Cancer Awareness Month, Charles Redfern, MD, discussed the biggest technological changes to treatment for adult patients with brain cancer and how holistic treatment remains important for treating this challenging disease.

Two genetically engineered gamma-delta T-cell therapies, INB-400 and INB-410, have been granted an orphan drug designation from the FDA for numerous types of malignant glioma.

The first orphan drug designation from the FDA has been received by FORE Biotherapeutics and for the FORE8394 program for patients with primary brain and central nervous system malignancies.

Findings from the phase 2 Study CDRB436G2201 trial have led the FDA to approve dabrafenib combined with trametinib for pediatric patients with BRAF V600E-mutated low-grade glioma who require systemic therapy.

Vorasidenib may break a 20-year gap in treatment advances for IDH-mutant low-grade glioma, according to phase 3 findings from the INDIGO study.

The FDA has granted the cell therapy temferon an orphan drug designation to treat patients with brain cancer.

Based on the FDA’s review of a new drug application, a phase 2 study will evaluate the safety and efficacy of azeliragon for patients with glioblastoma.

In an interview with Targeted Oncology, Patrick Wen, MD, discussed precision medicine for adult gliomas, including present and future treatment options.

In an interview with Targeted Oncology™, Manmeet Ahluwalia, MD, discussed the importance of the Inaugural Miami Cancer Institute Precision Medicine Oncology Symposium, what to expect from his presentation on brain metastases, and what to expect from presentations by other experts.

After more than 15 years with no new treatments for glioblastoma, a novel LSD1 small molecule has been granted orphan drug designation by the FDA.

Both pediatric brain cancers and sarcomas have an extremely dismal outcome in the relapse setting, according to Catherine Bollard, MD. A new Cancer Grand Challenge aims to address the issue with the development of new therapies.

Following positive data from the phase 1 ReSPECT-GBM trial, the first patient has been dosed with rhenium (186Re) obisbemeda in the phase 2 portion.

Azeliragon has been granted an orphan drug designation by the FDA for patients with glioblastoma after previous trials demonstrated the agent to be well-tolerated in Alzheimer’s disease.

Based on topline results from tovorafenib in the FIREFLY-1 study, the developer plans to file a new drug application with the FDA.

A prospective, blinded study confirmed the accuracy of the detecting brain tumors with the TriNetraTM-Glio test, addressing an unmet medical need for experts in this space.

Primary brain cancers are aggressive, resulting in low survival rates, and pose significant challenges to effective treatment, but ongoing studies signal hope for patients with there tumors.

DCVax-L was well tolerated and prolonged survival in patients with newly diagnosed and recurrent glioblastoma within the phase 3 trial.

A phase 1 trial evaluating 5-aminolevulinic acid and CV01 delivery of ultrasound has begun treating the first 3 of approximately 33 patients with recurrent high-grade glioma.

Ajaz M. Khan, MD, MBA, CPE, a medical oncologist and chair of the CTCA Department of Medical Oncology, explores available treatments for patients with well-differentiated neuroendocrine tumors.

In a unanimous vote, the FDA’s Oncologic Drugs Advisory Committee has voted that there is not enough evidence to conclude omburtamab improves overall survival in neuroblastoma with central nervous system/leptomeningeal metastases.

As part of the phase 2 INSIGhT trial, VBI Vaccines, Inc, and Agenus will examine the combination of VBI-1901 and balstilimab in patients with glioblastoma.

Distinguishing on current imaging between disease progression and pseudo progression in patients with glioblastoma is one of the most difficult clinical problems, according to Manmeet Ahluwalia, MD and Pallavi Tiwari, PhD.

Rhenium-186 nanoliposome at doses exceeding 100 Gy showed promising results in patients with recurrent glioma, according to phase 1 findings from the ReSPECT-GBM trial presented at ESMO 2022.

The combination of paxalisib and radiotherapy exhibited complete or partial responses in all patients with brain metastases, according to interim data from an ongoing phase I clinical trial.

An orphan drug designation has been granted to DSP-0390 by the FDA as treatment in patients with brain cancer.

Orphan drug designation has been granted to NT-I7 by the FDA for patients with glioblastoma multiforme.

An orphan drug designation and a fast track designation have been granted by the FDA to a novel sonodynamic therapy platform as a potential treatment for patients with recurrent glioblastoma and other malignant gliomas.

Rare pediatric disease designation has been awarded to paxalisib for the treatment of patients with atypical rhabdoid or teratoid tumors in rare and highly-aggressive childhood brain cancer.

Findings from 2 studies suggest that long-term survival is possible in a significant proportion of patients with a 1p/19q co-deleted oligodendroglioma.

An investigational bivalent gB/pp65 immunotherapeutic vaccine candidate has been granted orphan drug designation by the FDA for the treatment of patients with glioblastoma.